Epcoritamab Gives Deep Response in Richter’s Transformation

EPCORE CLL-1: epcoritamab in patients with R/R CLL & Richter's transformationПодробнее

Promising therapies for Richter's transformation: ven-R-CHOP, epcoritamab, pirtobrutinib & CAR-TПодробнее

Epcoritamab monotherapy and combinations in R/R CLL and Richter’s syndromeПодробнее

How to treat Richter’s transformationПодробнее

CLL: The Risk of Richter’s TransformationПодробнее

The current SoC in Richter’s transformation and the potential role of CAR T-cell therapyПодробнее

Early results from EPCORE CLL-1 trial: subcutaneous epcoritamab in patients with Richter’s syndromeПодробнее

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformationПодробнее

Promising agents emerging for Richter’s transformationПодробнее

Case 3: Therapeutic Approaches for Richter TransformationПодробнее

Efficacy and safety of glofitamab for patients with Richter’s transformationПодробнее

Treatment of Richter’s transformation: recent insightsПодробнее

Dr Nicholas Martinez discusses Richter's transformationПодробнее

Pirtobrutinib for Richter's Transformation - Dr. William Wierda ASH 2023Подробнее

Investigating the biology of Richter’s transformationПодробнее

Treating Richter’s transformation with venetoclax, obinutuzumab and atezolizumabПодробнее

Outcomes of patients with Richter's transformation without prior chemoimmunotherapy for CLL/SLLПодробнее

Phase I trial of copanlisib + nivolumab in patients with Richter’s transformation or transformed FLПодробнее